EZETIMIBE
All products: Limited Use (codes 380, 381)
Other products in the same Health Canada class (C10A, C10AX) — coverage varies; not interchangeable
- Alirocumab (Praluent): limited Use 555
- Evolocumab (Repatha): limited Use 527, 737
- Inclisiran (Leqvio): limited Use 732
- Atorvastatin (Lipitor): general benefit
- Bezafibrate (Bezalip): general benefit
- Cholestyramine resin (Questran Light 4g Pk): general benefit, Not a benefit
9 more in the class list below
AG-Ezetimibe · DIN 02475898 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Ezetimibe · DIN 02475898
Manufacturer: Angita Pharma Inc.; listing date 2020-10-30
Health Canada: Marketed since 2018-07-20 · brand AG-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Angita pharma inc. · schedule Prescription
AG-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96664 · Verify on the e-Formulary ↗ (DIN 02475898)
Source record
DIN 02475898: AG-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id ANG
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475898
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96664
Interchangeable products
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475898
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Ezetimibe · DIN 02425610 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Ezetimibe · DIN 02425610
Manufacturer: Accord Healthcare Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-17 · brand ACH-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Accord healthcare inc · schedule Prescription
Ach-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91025 · Verify on the e-Formulary ↗ (DIN 02425610)
Source record
DIN 02425610: Ach-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id ACH
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02425610
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91025
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2026-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02425610
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Ezetimibe · DIN 02427826 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Ezetimibe · DIN 02427826
Manufacturer: Apotex Inc.; listing date 2014-11-27
Health Canada: Marketed since 2026-08-14 · brand APO-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Apotex inc · schedule Prescription
Apo-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91232 · Verify on the e-Formulary ↗ (DIN 02427826)
Source record
DIN 02427826: Apo-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02427826
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91232
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: active shortage (reported 2023-12-05, last updated 2024-01-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02427826
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Ezetimibe · DIN 02469286 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Ezetimibe · DIN 02469286
Manufacturer: Auro Pharma Inc.; listing date 2018-07-31
Health Canada: Marketed since 2018-04-25 · brand AURO-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Auro pharma inc · schedule Prescription
Auro-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95800 · Verify on the e-Formulary ↗ (DIN 02469286)
Source record
DIN 02469286: Auro-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469286
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95800
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2024-11-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469286
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Bio-Ezetimibe · DIN 02425211 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Ezetimibe · DIN 02425211
Manufacturer: Biomed Pharma; listing date 2026-07-31
Health Canada: Marketed since 2014-10-08 · brand BIO-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Biomed pharma · schedule Prescription
Bio-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90986 · Verify on the e-Formulary ↗ (DIN 02425211)
Source record
DIN 02425211: Bio-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id BMP
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02425211
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90986
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2020-02-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02425211
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ezetimibe · DIN 02431300 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ezetimibe · DIN 02431300
Manufacturer: Sanis Health Inc.; listing date 2020-05-29
Health Canada: Marketed since 2022-08-04 · brand EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Sanis health inc · schedule Prescription
Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91572 · Verify on the e-Formulary ↗ (DIN 02431300)
Source record
DIN 02431300: Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02431300
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91572
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: anticipated shortage (last updated 2026-05-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02431300
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ezetrol · DIN 02247521 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Ezetrol (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Ezetrol · DIN 02247521
Manufacturer: Organon Canada Inc.; listing date 2004-04-06
Health Canada: Marketed since 2022-04-22 · brand EZETROL · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71771 · Verify on the e-Formulary ↗ (DIN 02247521)
Source record
DIN 02247521: Ezetrol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id OCI
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $2.2508; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247521
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71771
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2024-11-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247521
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Ezetimibe · DIN 02423235 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Ezetimibe · DIN 02423235
Manufacturer: Jamp Pharma Corporation; listing date 2014-11-27
Health Canada: Marketed since 2014-09-15 · brand JAMP-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90797 · Verify on the e-Formulary ↗ (DIN 02423235)
Source record
DIN 02423235: Jamp-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423235
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90797
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2026-03-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423235
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Ezetimibe · DIN 02467437 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Ezetimibe · DIN 02467437
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Health Canada: Marketed since 2017-12-14 · brand M-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Mantra pharma inc · schedule Prescription
M-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95581 · Verify on the e-Formulary ↗ (DIN 02467437)
Source record
DIN 02467437: M-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id MAT
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467437
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95581
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: discontinued (2020-04-07, reported by MANTRA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02467437
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Ezetimibe · DIN 02422662 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Ezetimibe · DIN 02422662
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-15 · brand MAR-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90733 · Verify on the e-Formulary ↗ (DIN 02422662)
Source record
DIN 02422662: Mar-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id MAR
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02422662
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90733
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2019-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02422662
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Ezetimibe · DIN 02423243 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Ezetimibe · DIN 02423243
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-15 · brand MINT-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90798 · Verify on the e-Formulary ↗ (DIN 02423243)
Source record
DIN 02423243: Mint-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id MIN
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423243
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90798
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2017-11-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423243
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Ezetimibe Tablets · DIN 02536420 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Ezetimibe Tablets · DIN 02536420
Manufacturer: Nora Pharma; listing date 2024-04-30
Health Canada: Marketed since 2024-01-11 · brand NRA-EZETIMIBE TABLETS · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Nora pharma inc · schedule Prescription
NRA-Ezetimibe Tablets: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102520 · Verify on the e-Formulary ↗ (DIN 02536420)
Source record
DIN 02536420: NRA-Ezetimibe Tablets
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id NRA
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536420
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102520
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536420
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Ezetimibe · DIN 02416409 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Ezetimibe · DIN 02416409
Manufacturer: Pharmascience Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-15 · brand PMS-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Pharmascience inc · schedule Prescription
PMS-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90096 · Verify on the e-Formulary ↗ (DIN 02416409)
Source record
DIN 02416409: PMS-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02416409
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90096
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2026-08-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416409
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Ezetimibe · DIN 02419548 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Ezetimibe · DIN 02419548
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2014-11-27
Health Canada: Marketed since 2026-03-11 · brand SPC-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Sun pharma canada inc · schedule Prescription
Ran-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90416 · Verify on the e-Formulary ↗ (DIN 02419548)
Source record
DIN 02419548: Ran-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id RAN
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02419548
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90416
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2025-10-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02419548
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Ezetimibe · DIN 02416778 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Ezetimibe · DIN 02416778
Manufacturer: Sandoz Canada Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-15 · brand SANDOZ EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90134 · Verify on the e-Formulary ↗ (DIN 02416778)
Source record
DIN 02416778: Sandoz Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id SDZ
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02416778
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90134
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2024-11-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416778
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Ezetimibe · DIN 02354101 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Ezetimibe · DIN 02354101
Manufacturer: Teva Canada Limited; listing date 2014-11-27
Health Canada: Marketed since 2014-09-15 · brand TEVA-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Teva canada limited · schedule Prescription
Teva-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83931 · Verify on the e-Formulary ↗ (DIN 02354101)
Source record
DIN 02354101: Teva-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id TEV
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354101
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83931
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02354101
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ezetimibe · DIN 02429659 · 10mg · tablet
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ezetimibe · DIN 02429659
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30
Health Canada: Dormant since 2026-07-03 · brand EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91410 · Verify on the e-Formulary ↗ (DIN 02429659)
Source record
DIN 02429659: Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429659
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91410
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: active shortage (reported 2026-01-13, last updated 2026-01-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429659
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-03 — choose a marketed DIN from the same-category list.
GLN-Ezetimibe · DIN 02460750 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 requiredDormant since 2025-06-19 · checked 2026-09-19
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
GLN-Ezetimibe · DIN 02460750
Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2020-12-18
Health Canada: Dormant since 2025-06-19 · brand GLN-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription
GLN-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94824 · Verify on the e-Formulary ↗ (DIN 02460750)
Source record
DIN 02460750: GLN-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id GLP
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02460750
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94824
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02460750
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-06-19 — choose a marketed DIN from the same-category list.
Act Ezetimibe · DIN 02414716 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 required; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.Discontinued 2018-06-12 · checked 2026-09-19
StatusLimited Use — Reason for Use code 380, 381 required; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Write on scriptLU code 380, 381 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Act Ezetimibe · DIN 02414716
Manufacturer: Actavis Pharma Company; listing date 2014-11-27
Health Canada: Cancelled post market since 2018-06-12 · brand ACT EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Actavis pharma company · schedule Prescription
Act Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89935 · Verify on the e-Formulary ↗ (DIN 02414716)
Source record
DIN 02414716: Act Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id ACV
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02414716
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89935
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2017-05-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02414716
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
NRA-Ezetimibe · DIN 02481669 · 10mg · tablet
Limited Use — Reason for Use code 380, 381 required; Health Canada lists this DIN as Cancelled post market since 2025-01-31 — choose a marketed DIN from the same-category list.Discontinued 2025-01-31 · checked 2026-09-02
StatusLimited Use — Reason for Use code 380, 381 required; Health Canada lists this DIN as Cancelled post market since 2025-01-31 — choose a marketed DIN from the same-category list.
Write on scriptLU code 380, 381 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2025-01-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Ezetimibe · DIN 02481669
Manufacturer: Nora Pharma; listing date 2020-06-30
Health Canada: Cancelled post market since 2025-01-31 · brand NRA-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Nora pharma inc · schedule Prescription
NRA-Ezetimibe: Formulary list price $0.1811/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1811 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97215 · Verify on the e-Formulary ↗ (DIN 02481669)
Source record
DIN 02481669: NRA-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id NRA
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481669
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97215
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Ach-Ezetimibe · DIN 02425610 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02481669
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-01-31 — choose a marketed DIN from the same-category list.